CFI-402257

N/A

Report date: 2023/01/11 09:11:54
NME

Base Information

Drug NameCFI-402257
Drug Alias NameCFI-402257
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity protein kinase TTK inhibitors
TargetsDual specificity protein kinase TTK
Therapy Area/IndicationsSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Health Network (Uhn)
China Registration ClassN/A

Develop Information

Active CompaniesOntario Institute For Cancer ResearchCanadian Cancer Trials GroupTreadwell Therapeutics Inc +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A